Literature DB >> 12373013

Growth in disorders of adrenal hyperfunction.

M O Savage1, S Scommegna, P V Carroll, J T F Ho, J P Monson, G M Besser, A B Grossman.   

Abstract

Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 +/- 0.42 and 1.3 +/- 0.37 SDS respectively. In poorly controlled CAH, excess androgens cause early epiphyseal fusion and adult short stature. Increased growth occurs only after 18 months of age, even in untreated CAH, i.e. hydrocortisone >10 mg/m(2)/day is not generally required and may suppress infantile growth, affecting childhood and adult height. Growth was studied in 19 patients, aged 6.4-17.8 years, with Cushing's disease (CD). At diagnosis, mean height SDS was -1.81 (1.2 to -4.17), 53% < -1.8 SDS, height velocity in 6 was 0.9-3.8 cm/year and mean BMI SDS 2.29 (0.7-5.06). From 1983 to 2001, CD was cured in 18 patients (61%) by transsphenoidal surgery (TSS) alone and 39% by TSS plus pituitary irradiation (RT). In 13 patients, growth hormone (GH) was assessed by ITT/glucagons at 1-108 months after cure. Four had severe GH deficiency (<9 mU/l), 7 subnormal (10-29 mU/l) and 2 normal (>30 mU/l) GH status. Subnormal GH was present in 7 subjects >2 years after TSS or RT cure. In 10 subjects, aged 12.9 +/- 3.4 years, growth after cure was studied for 9.1 +/- 5.0 years. Nine had no catch-up growth in the interval of 0.3-1.1 years after cure (mean HV 5.3 +/- 2.4 cm/year). All these had GH deficiency peak GH 0.5-20.9 mU/l, and received hGH 2.7 mg/m(2)/week, 3 with GnRHa. All 10 showed long-term catch-up growth with mean delta SDS at diagnosis (Ht SDS-target Ht SDS) -1.72 +/- 1.26 improving to -0.83 +/- 1.08 (p = 0.0005) at latest of final Ht. At diagnosis, virilization was present in 82% of 17 patients with CD. Mean SDS values of serum androstenedione, DHEA-S and testosterone were normal, i.e. 0.72 (-2.9 to 3.0), -0.8 (6.0 to 2.2), 0.7 (-7.9 to 9.5) respectively, whereas SHBG was reduced at -2.1 (-5.3 to 1.2), increasing free androgen levels. Bone age (BA) was delayed (mean 1.46 years) in 14/16 patients, suggesting cortisol excess contributed more then androgen effect to skeletal maturation. In conclusion, most paediatric patients with CD had subnormal linear growth with delayed BA. After cure by TSS or pituitary irradiation, GH deficiency was frequent and persisted for many years. Treatment with hGH induced significant long-term catch-up growth leading to reasonable final height. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373013     DOI: 10.1159/000064767

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  7 in total

1.  Use of desmopressin as an alternative to corticotropin-releasing hormone during inferior petrosal sinus sampling in a child with Cushing's disease.

Authors:  M H Gannagé-Yared; S Slaba; T Rizk; R-M Chidiac Wehbe
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

Review 2.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

3.  Tactile/kinesthetic stimulation (TKS) increases tibial speed of sound and urinary osteocalcin (U-MidOC and unOC) in premature infants (29-32weeks PMA).

Authors:  S Haley; J Beachy; K K Ivaska; H Slater; S Smith; L J Moyer-Mileur
Journal:  Bone       Date:  2012-07-27       Impact factor: 4.398

4.  Massage improves growth quality by decreasing body fat deposition in male preterm infants.

Authors:  Laurie J Moyer-Mileur; Shannon Haley; Hillarie Slater; Joanna Beachy; Sandra L Smith
Journal:  J Pediatr       Date:  2012-10-11       Impact factor: 4.406

5.  Gonadotropin-dependent pubertal disorders are common in patients with virilizing adrenocortical tumors in childhood.

Authors:  Monica F Stecchini; Zilda Braid; Candy B More; Davi C Aragon; Margaret Castro; Ayrton C Moreira; Sonir R Antonini
Journal:  Endocr Connect       Date:  2019-05-01       Impact factor: 3.335

6.  A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.

Authors:  Somya Verma; Carol Vanryzin; Ninet Sinaii; Mimi S Kim; Lynnette K Nieman; Shayna Ravindran; Karim A Calis; Wiebke Arlt; Richard J Ross; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-25       Impact factor: 3.478

Review 7.  Adult-Onset Diseases in Low Birth Weight Infants: Association with Adipose Tissue Maldevelopment.

Authors:  Yuya Nakano
Journal:  J Atheroscler Thromb       Date:  2019-12-20       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.